Intelligence Feed event · Equity · 2026-10-04

    Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trial

    Question

    Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trial

    Direct answer

    Genmab announced clinical outcomes from the Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The data showed an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and a median progression-free survival of 9.5 months, confirming clinical efficacy in a refractory setting.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-reports-45-9-orr-and-9-5-month-pfs-in-phase-2-platinum-resistant-ovarian-275c62

    EQUITY
    Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trial
    Genmab announced clinical outcomes from the Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The data showed an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and a median progression-free survival of 9.5 months, confirming clinical efficacy in a refractory setting.
    GMAB
    Impact
    72
    OCT 4
    SIG
    92%
    GMAB
    Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trial
    Genmab announced clinical outcomes from the Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The data showed an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and a median progression-free survival of 9.5 months, confirming clinical efficacy in a refractory setting.
    → Positive Phase 2 oncology trial data enhances the commercial net present value of Genmab's proprietary ADC pipeline.
    Impact
    Genmab announced clinical outcomes from the Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The data showed an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and a median progression-free survival of 9.5 months, confirming clinical efficacy in a refractory setting.
    Affected
    GMAB
    Transmission
    Positive Phase 2 oncology trial data enhances the commercial net present value of Genmab's proprietary ADC pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABpipeline net present value repricing on positive Phase 2 clinical readoutUp1-5d45.9% ORR and 9.5-month median PFS reported in RAINFOL-01 trial.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month